Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Operating Expenses (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Operating Expenses for 11 consecutive years, with $794436.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses fell 77.95% year-over-year to $794436.0, compared with a TTM value of $8.1 million through Sep 2025, down 26.92%, and an annual FY2024 reading of $11.5 million, down 8.56% over the prior year.
  • Operating Expenses was $794436.0 for Q3 2025 at Kiora Pharmaceuticals, down from $2.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $6.4 million in Q4 2021 and bottomed at $794436.0 in Q3 2025.
  • Average Operating Expenses over 5 years is $3.0 million, with a median of $2.6 million recorded in 2023.
  • The sharpest move saw Operating Expenses surged 439.17% in 2021, then plummeted 77.95% in 2025.
  • Year by year, Operating Expenses stood at $6.4 million in 2021, then crashed by 41.88% to $3.7 million in 2022, then plummeted by 42.79% to $2.1 million in 2023, then rose by 21.05% to $2.6 million in 2024, then tumbled by 69.02% to $794436.0 in 2025.
  • Business Quant data shows Operating Expenses for KPRX at $794436.0 in Q3 2025, $2.4 million in Q2 2025, and $2.3 million in Q1 2025.